Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the USA
April 29 (Reuters) - Cullinan Therapeutics Inc CGEM.O:
CULLINAN THERAPEUTICS TO INITIATE STUDY OF CLN-978, A BISPECIFIC CD19 T CELL ENGAGER ADMINISTERED SUBCUTANEOUSLY, IN PATIENTS WITH SJÖGREN’S DISEASE IN THE UNITED STATES
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.